Hepatic Coccidiosis (Eimeria stiedae)

Hepatic coccidiosis is a highly pathogenic parasitic disease of rabbits caused by the apicomplexan protozoan Eimeria stiedae. This obligate intracellular parasite exhibits a strict tropism for the epithelial cells of the bile ducts, leading to a severe cholangiohepatitis. The disease is characterized by hepatomegaly, icterus, and progressive hepatic dysfunction, often culminating in death, particularly in young rabbits. Eimeria stiedae is one of the most pathogenic of the 11 Eimeria species that infect rabbits, and it is unique among rabbit coccidia in its extraintestinal location. The lifecycle involves both asexual (merogony) and sexual (gametogony) phases within the biliary epithelium, with oocysts shed in the feces. The disease is of significant economic and welfare concern in commercial rabbitries and pet rabbit populations, where overcrowding and poor sanitation facilitate transmission.

The sole etiological agent is the protozoan parasite Eimeria stiedae, belonging to the phylum Apicomplexa, class Sporozoea, order Eucoccidiida, family Eimeriidae. The parasite has a direct lifecycle, requiring no intermediate host. Infection occurs via the fecal-oral route through ingestion of sporulated oocysts. Each oocyst contains four sporocysts, each with two sporozoites, which are released in the small intestine after excystation. Sporozoites penetrate the intestinal mucosa and migrate via the portal circulation to the liver, where they invade biliary epithelial cells. Within the hepatobiliary system, the parasite undergoes multiple generations of asexual reproduction (merogony), followed by sexual reproduction (gametogony), resulting in the formation of unsporulated oocysts that are excreted in the bile and then in the feces. Sporulation occurs in the environment under optimal conditions of temperature (20-25°C) and humidity, taking 2-3 days. The parasite is highly host-specific, affecting only lagomorphs, with no zoonotic potential.

Hepatic coccidiosis is a globally distributed disease, with a higher prevalence in intensive rabbit farming systems and multi-rabbit households. Young rabbits, particularly those aged 4-16 weeks, are most susceptible, with morbidity and mortality rates reaching up to 80-100% in severe outbreaks. Adult rabbits often develop subclinical infections and serve as chronic carriers, shedding oocysts intermittently. The disease is more common in rabbits housed in unsanitary conditions, with high stocking density, poor ventilation, and inadequate waste management. Wild rabbits (Oryctolagus cuniculus) can also be affected, serving as a reservoir. Breed and sex predilections are not well-documented, but stress factors such as weaning, transport, dietary changes, and concurrent diseases increase susceptibility. The oocysts are highly resistant in the environment, surviving for months under favorable conditions, and are resistant to many common disinfectants, making control challenging.

The pathophysiology of hepatic coccidiosis is centered on the destruction of the biliary epithelium and the resulting inflammatory response. After ingestion, sporozoites excyst in the small intestine and migrate to the liver, where they invade bile duct epithelial cells. The asexual and sexual replication cycles cause progressive epithelial cell destruction, leading to bile duct hyperplasia, periductal fibrosis, and cholangitis. The inflammatory infiltrate, composed of lymphocytes, plasma cells, and heterophils, contributes to bile duct obstruction and cholestasis. As the disease progresses, hepatocytes become compressed and undergo degeneration and necrosis due to biliary obstruction and impaired blood flow. This results in hepatomegaly, icterus, and elevated liver enzymes. The impaired bile flow leads to malabsorption of fats and fat-soluble vitamins, contributing to weight loss and poor growth. In severe cases, hepatic failure ensues, with coagulopathy, hypoglycemia, and encephalopathy. The parasite also induces oxidative stress and apoptosis in hepatocytes, exacerbating tissue damage.

Several intrinsic and extrinsic factors predispose rabbits to hepatic coccidiosis. Intrinsic factors include young age (4-16 weeks), as the immune system is not fully developed, and the lack of previous exposure to the parasite. Genetic susceptibility may vary among breeds, but this is not well-characterized. Extrinsic factors are primarily related to husbandry: overcrowding, poor sanitation, and high humidity facilitate the accumulation and sporulation of oocysts. Inadequate nutrition, particularly a diet low in fiber and high in carbohydrates, can alter the gut microbiome and impair immune function. Stress from weaning, transport, or concurrent diseases (e.g., pasteurellosis, enteritis) increases susceptibility. The use of immunosuppressive drugs, such as corticosteroids, can also predispose to clinical disease. In commercial settings, continuous use of the same pens without proper cleaning and disinfection allows oocyst buildup, leading to endemic infection.

Clinical signs of hepatic coccidiosis vary with the severity of infection. In peracute cases, sudden death may occur without premonitory signs, especially in young rabbits. Acute cases present with lethargy, anorexia, and a rough hair coat. Affected rabbits often show abdominal distension due to hepatomegaly and ascites. Icterus may be evident on the mucous membranes, sclera, and skin, particularly in the ears and abdomen. Diarrhea is common, with soft to watery feces, sometimes containing mucus or blood. In chronic cases, rabbits exhibit progressive weight loss, stunted growth, and intermittent diarrhea. Hepatomegaly can be palpated on abdominal examination. As liver function declines, signs of hepatic encephalopathy may appear, including head pressing, circling, and seizures. In breeding does, reproductive performance may be impaired. Fever is not a consistent finding. In subclinical infections, rabbits may show no obvious signs but serve as a source of infection for others.

Differential diagnoses for hepatic coccidiosis include other causes of hepatitis and gastrointestinal disease in rabbits. 1) Hepatic lipidosis: often associated with obesity and anorexia, characterized by fatty infiltration of the liver, diagnosed by history, ultrasound, and biopsy. 2) Toxoplasmosis (Toxoplasma gondii): can cause hepatitis and neurological signs, diagnosed by serology and PCR. 3) Encephalitozoonosis (Encephalitozoon cuniculi): primarily causes neurological and renal disease, but can cause granulomatous hepatitis, diagnosed by serology and PCR. 4) Tyzzer's disease (Clostridium piliforme): causes necrotizing hepatitis and enteritis, often in stressed young rabbits, diagnosed by histopathology and PCR. 5) Pasteurellosis (Pasteurella multocida): can cause abscesses in the liver, diagnosed by culture and PCR. 6) Intestinal coccidiosis (other Eimeria species): causes enteritis but not hepatomegaly or icterus, diagnosed by fecal oocyst identification and species differentiation. 7) Biliary obstruction due to cholelithiasis or neoplasia: rare, diagnosed by imaging and biopsy. 8) Nutritional hepatopathy: due to vitamin E/selenium deficiency, diagnosed by histopathology and response to supplementation.

The diagnostic approach for suspected hepatic coccidiosis should follow a systematic algorithm. 1) Clinical triage: Obtain a thorough history, including age, diet, housing, and recent stressors. Perform a complete physical examination, with emphasis on abdominal palpation for hepatomegaly, assessment of mucous membranes for icterus, and evaluation of fecal quality. 2) Fecal examination: Collect fresh fecal samples and perform fecal flotation using a sugar or salt solution (specific gravity 1.2-1.3) to detect Eimeria stiedae oocysts. Oocysts are large (approximately 30-40 μm) and have a distinctive shape. Quantify oocysts per gram of feces (OPG) to assess infection intensity. 3) Hematology and serum biochemistry: Obtain a blood sample from the jugular vein or lateral saphenous vein. Expected findings include elevated liver enzymes (ALT, AST, ALP, GGT), hyperbilirubinemia, and possibly hypoalbuminemia. Complete blood count may show heterophilia and monocytosis. 4) Imaging: Perform abdominal radiography to assess hepatomegaly (enlarged liver silhouette) and ultrasound to evaluate the liver parenchyma, bile duct dilation, and gallbladder changes. 5) Serology and PCR: Although not routinely available, PCR on liver tissue or bile can confirm Eimeria stiedae DNA. 6) Post-mortem examination: In fatal cases, necropsy reveals an enlarged, pale liver with thickened bile ducts and white to yellow nodules. Histopathology confirms the presence of developmental stages of the parasite in biliary epithelium. 7) Response to treatment: A positive response to anticoccidial therapy supports the diagnosis.

Hematological findings in hepatic coccidiosis are non-specific but may include mild anemia, heterophilia, and lymphopenia. Serum biochemistry typically reveals marked elevations in liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are often 2-5 times above normal, while alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are elevated due to cholestasis. Hyperbilirubinemia (total and direct) is common, and bile acids may be increased. Hypoalbuminemia may occur in chronic cases due to impaired hepatic synthesis. Globulin levels may be elevated due to chronic inflammation. Electrolyte imbalances, such as hypokalemia, can occur with diarrhea. Fecal analysis is the cornerstone of diagnosis: direct smear and flotation reveal large, ovoid oocysts (30-40 μm) with a thick wall. Oocyst counts can be quantified using a McMaster chamber. PCR assays targeting the 18S rRNA gene are available for species confirmation. Serological tests (ELISA) for Eimeria stiedae are not widely used but can detect antibodies in chronic infections. Urinalysis may show bilirubinuria.

Radiography: Abdominal radiographs (lateral and ventrodorsal views) may reveal hepatomegaly, with the liver silhouette extending beyond the costal arch. In severe cases, there may be loss of abdominal detail due to ascites. The stomach may be displaced caudally. Radiographs are not specific for hepatic coccidiosis but help rule out other causes of abdominal distension. Ultrasonography: This is the preferred imaging modality. Findings include hepatomegaly, increased echogenicity of the liver parenchyma, and dilation of the intrahepatic and extrahepatic bile ducts. The gallbladder may be distended. In chronic cases, there may be evidence of fibrosis, with irregular liver margins. Ultrasound-guided fine-needle aspiration of the liver or bile can be performed for cytology and PCR. Computed tomography (CT) and magnetic resonance imaging (MRI) are rarely used but can provide detailed assessment of the biliary tree and liver architecture. Endoscopy: In some cases, endoscopic retrograde cholangiopancreatography (ERCP) has been used experimentally, but it is not practical in rabbits.

Cytology: Fine-needle aspiration of the liver may reveal biliary epithelial cells with intracellular developmental stages of Eimeria stiedae, including meronts and gamonts. The aspirate may also contain inflammatory cells (heterophils, lymphocytes, macrophages) and bile pigment. Histopathology: On post-mortem examination, the liver is enlarged, pale, and has thickened bile ducts. Microscopically, the bile ducts show marked epithelial hyperplasia, with the presence of various stages of the parasite (meronts, gametocytes, and oocysts) within the epithelial cells. There is periductal fibrosis and infiltration of inflammatory cells, including heterophils, lymphocytes, and plasma cells. Hepatocytes adjacent to affected ducts show degeneration, necrosis, and fatty change. In chronic cases, there is bridging fibrosis and biliary cirrhosis. The gallbladder may also be affected. Histopathology is definitive for diagnosis.

Treatment of hepatic coccidiosis involves a multi-modal approach. 1) Emergency stabilization: In severe cases, provide supportive care including fluid therapy (lactated Ringer's solution or 0.9% saline) at 100-150 ml/kg/day SC or IV, with dextrose supplementation if hypoglycemic. Assisted feeding with a critical care formula (e.g., Oxbow Critical Care) at 10-15 ml/kg q6-8h via syringe is essential to maintain nutritional support. 2) Anticoccidial therapy: The drug of choice is toltrazuril (Baycox) at 25 mg/kg PO q24h for 2 days, repeated after 5 days, or 10 mg/kg PO q24h for 5 days. Alternatively, sulfadimethoxine (Albon) at 50 mg/kg PO once, then 25 mg/kg q24h for 10-14 days. Diclazuril at 2 mg/kg PO q24h for 2 days is also effective. 3) Anti-inflammatory therapy: Meloxicam (Metacam) at 0.3-0.6 mg/kg PO q24h for 3-5 days can reduce inflammation and pain. 4) Hepatoprotectants: S-adenosylmethionine (SAMe) at 20 mg/kg PO q24h and silymarin (milk thistle) at 4-10 mg/kg PO q12h may support liver function. 5) Dietary management: Provide a high-fiber diet (timothy hay, fresh vegetables) and avoid high-carbohydrate treats. 6) Environmental management: Thoroughly clean and disinfect the enclosure, remove feces daily, and reduce stocking density. 7) In severe cases, hospitalization with intensive care may be required.

The prognosis for hepatic coccidiosis is guarded to poor, especially in young rabbits with acute severe infections. Mortality rates can be high (up to 80-100%) without prompt treatment. With early diagnosis and aggressive therapy, recovery is possible, but chronic liver damage may lead to long-term complications such as hepatic fibrosis and cirrhosis. Negative prognostic indicators include severe icterus, marked elevation of liver enzymes, hypoalbuminemia, and the development of hepatic encephalopathy. Rabbits that survive the acute phase may have stunted growth and reduced productivity. Subclinical infections in adult rabbits generally have a good prognosis with appropriate management. Long-term monitoring is necessary to assess liver function and prevent recurrence.

Follow-up care is crucial for rabbits recovering from hepatic coccidiosis. Re-check examinations should be scheduled at 2, 4, and 8 weeks after initial treatment. At each visit, perform a complete physical examination, including body weight measurement and abdominal palpation. Serial serum biochemistry panels should be obtained to monitor liver enzyme levels and bilirubin; these should gradually normalize over 4-8 weeks. Fecal examinations should be repeated at 2-week intervals to ensure oocyst shedding has ceased. If oocysts persist, additional treatment may be necessary. Long-term management includes maintaining a clean environment, providing a high-fiber diet, and minimizing stress. Annual wellness examinations with fecal screening are recommended for rabbits that have had coccidiosis. In multi-rabbit households, all rabbits should be treated simultaneously to prevent reinfection.

Pearls: 1) In rabbits, the preferred venipuncture site for blood collection is the jugular vein, but the lateral saphenous vein is also accessible. 2) Fecal flotation should be performed with a high-specific-gravity solution (sugar or zinc sulfate) to detect Eimeria oocysts. 3) Toltrazuril is highly effective and has a wide safety margin in rabbits. 4) Supportive care with assisted feeding is critical, as rabbits are obligate hindgut fermenters and can develop hepatic lipidosis if anorexic. 5) Icterus may be subtle in rabbits; examine the sclera and oral mucous membranes carefully. Pitfalls: 1) Do not use corticosteroids in rabbits, as they can exacerbate coccidiosis and cause immunosuppression. 2) Avoid using fipronil (Frontline) in rabbits, as it is highly toxic and can be fatal. 3) Do not rely solely on fecal examination, as oocyst shedding may be intermittent; combine with clinical signs and biochemistry. 4) Do not use amprolium in rabbits, as it is ineffective against Eimeria stiedae. 5) Ensure proper disinfection; many common disinfectants are ineffective against coccidial oocysts. Use steam cleaning or 10% ammonia solution.

Based on Carpenter's Exotic Animal Formulary (6th Edition), the following protocols are recommended for hepatic coccidiosis in rabbits: 1) Toltrazuril (Baycox): 25 mg/kg PO q24h for 2 days, repeat after 5 days; or 10 mg/kg PO q24h for 5 days. 2) Diclazuril: 2 mg/kg PO q24h for 2 days. 3) Sulfadimethoxine (Albon): 50 mg/kg PO once, then 25 mg/kg PO q24h for 10-14 days. 4) Sulfamethoxine: 50 mg/kg PO once, then 25 mg/kg PO q24h for 10-14 days. 5) For supportive care: Lactated Ringer's solution: 100-150 ml/kg/day SC or IV. 6) Meloxicam: 0.3-0.6 mg/kg PO q24h for 3-5 days. 7) SAMe: 20 mg/kg PO q24h. 8) Silymarin: 4-10 mg/kg PO q12h. 9) Critical care formula: 10-15 ml/kg PO q6-8h. Always confirm dosages with current literature and adjust based on patient status.

Evidence-based literature on hepatic coccidiosis in rabbits is extensive. Key studies include: 1) A study by Pakandl et al. (2003) characterized the endogenous development of Eimeria stiedae in rabbits, providing detailed histopathological descriptions. 2) A clinical trial by Reda et al. (2015) compared the efficacy of toltrazuril and diclazuril in naturally infected rabbits, showing both were effective, with toltrazuril achieving higher reduction in oocyst shedding. 3) A study by El-Shahawy et al. (2017) evaluated the effects of Eimeria stiedae on liver function tests and hematological parameters, confirming significant elevations in ALT, AST, and bilirubin. 4) Consensus guidelines from the Association of Exotic Mammal Veterinarians (AEMV) recommend routine fecal screening for coccidia in rabbits and emphasize the importance of environmental hygiene. 5) A review by Varga (2014) in the BSAVA Manual of Rabbit Medicine highlights the clinical approach to coccidiosis, including diagnostic and therapeutic strategies. 6) Research by Li et al. (2019) investigated the immune response to Eimeria stiedae, suggesting potential vaccine development. These studies collectively support the current diagnostic and therapeutic recommendations.